Prasugrel vs. clopidogrel in contemporary Western European patients with acute coronary syndromes receiving drug-eluting stents: Comparative cost-effectiveness analysis from the BASKET-PROVE cohorts-Reference-Cited by-同舟云学术

Prasugrel vs. clopidogrel in contemporary Western European patients with acute coronary syndromes receiving drug-eluting stents: Comparative cost-effectiveness analysis from the BASKET-PROVE cohorts

Published:2017-12 Issue: Volume:248 Page:20-27
ISSN:0167-5273
Container-title:International Journal of Cardiology
language:en
Short-container-title:International Journal of Cardiology

Author:

Wein Bastian^ORCID,Coslovsky Michael,Jabbari Reza,Galatius Søren,Pfisterer Matthias^ORCID,Kaiser Christoph

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference29 articles.

1. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation;Steg;Eur. Heart J.,2012

2. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

3. Prasugrel versus clopidogrel in patients with acute coronary syndromes;Wiviott;N. Engl. J. Med.,2007

4. Cost-Effectiveness of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndromes and Planned Percutaneous Coronary Intervention

5. Prasugrel vs clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a model-based cost-effectiveness analysis for Germany, Sweden, the Netherlands, and Turkey;Davies;J. Med. Econ.,2013

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comprehensive comparative efficacy and safety of potent P2Y12 inhibitors in patients undergoing coronary intervention: A systematic review and meta-analysis;IJC Heart & Vasculature;2024-04

2. Bleeding risk in patients prescribed dual antiplatelet therapy and triple therapy after coronary interventions: the ADAPTT retrospective population-based cohort studies;Health Technology Assessment;2023-05

3. Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk;Circulation: Cardiovascular Quality and Outcomes;2019-01

4. Prevalence, long-term prognosis and medical alternatives for patients admitted for acute coronary syndromes and prasugrel contraindication;International Journal of Cardiology;2018-11

5. Cost-effectiveness of prasugrel versus clopidogrel in acute coronary syndrome patients undergoing percutaneous coronary intervention;International Journal of Cardiology;2018-01